Ngalaba Mba Nile

Na Eprel 25, 2025, InnoCare Pharma kwupụtara na Center for Drug Evaluation (CDE) nke China National Medical Products Administration (NMPA) enyela nyocha mbụ nke ọgwụ mgbochi pan-TRK ọhụrụ ya nke zurletrectinib (ICP-723), nke nabatara ngwa ọgwụ ọhụrụ (NDA) nke z...GỤKWUO»

Na Eprel 25, 2025, Innovent Biologics kwupụtara na National Medical Products Administration (NMPA) nke China akwadola Ngwa Ọgwụ Ọhụrụ (NDA) maka limertinib dị ka ọgwụgwọ mbụ maka ndị okenye nwere ọrịa kansa akpa ume nke na-abụghị obere mkpụrụ ndụ (NSCLC) nke dị n'ógbè ahụ ma ọ bụ nke na-agbasa...GỤKWUO»

N'abalị iri abụọ na atọ nke ọnwa Eprel, penpulimab nke Akeso nwetara nkwenye site na iji cisplatin ma ọ bụ carboplatin na gemcitabine maka ọgwụgwọ mbụ nke ndị toro eto nwere ọrịa kansa nasopharyngeal na-abụghị keratinizing (NPC) na-emegharị ma ọ bụ na-akpata ọrịa kansa. FDA kwadokwara penpulimab-kcqx dị ka mmehie...GỤKWUO»

Na Machị 16, 2025, Akeso kwupụtara na National Medical Products Administration (NMPA) akwadola ọgwụ mgbochi PD-1 monoclonal antibody ọhụrụ ya, penpulimab, maka ọgwụgwọ mbụ nke kansa nasopharyngeal relapse maọbụ metastatic metastatic na njikọta ...GỤKWUO»

Na Eprel 24, 2025, GenFleet Therapeutics kwupụtara na US Food and Drug Administration (FDA) kwadoro ojiji ọgwụ ọhụrụ (IND) nke GFH375/VS-7375, ọgwụ mgbochi KRAS G12D (ON/OFF) nke a na-aṅụ, maka nnwale ahụike maka ịgwọ ndị ọrịa kansa siri ike nwere mgbanwe KRAS G12D. Ọmụmụ ihe a...GỤKWUO»

Na Eprel 17, 2025, Hansoh Pharmaceutical kwupụtara na ọgwụ B7-H3 nke otu ahụ mepụtara n'onwe ya maka ọgwụ mgbochi-ọgwụ (ADC) HS-20093 maka ịgba ọgwụ enwetala ikike itinye ya dị ka ọgwụ Breakthrough-Therapy-Designed site na National Medical Products Administration (NMPA) nke China, ...GỤKWUO»

Na Eprel 15, 2025, InnoCare Pharma kwupụtara na Center for Drug Evaluation (CDE) nke China National Medical Products Administration (NMPA) nabatara Ngwa Ọgwụ Ọhụrụ (NDA) maka ọgbọ ọhụrụ ya nke pan-TRK inhibitor zurletrectinib (ICP-723) maka ọgwụgwọ nke ndị okenye na ndị ntorobịa...GỤKWUO»

N'oge na-adịbeghị anya, GenFleet kwupụtara data nkebi nke abụọ kachasị ọhụrụ nke ọmụmụ KROCUS, fulzerasib (GFH925, KRAS G12C inhibitor) yana cetuximab maka ọgwụgwọ ọrịa kansa akpa ume nke mbụ na-abụghị obere sel (NSCLC), na nchịkọta ikpeazụ na obere ngosipụta ọnụ nke European Lung Cancer Conf 2025...GỤKWUO»

PLB1004, nke Beijing Avistone Biotechnology Co., Ltd. mepụtara, bụ ihe nchekwa, nhọrọ dị oke elu, na nke na-adịghị agbanwe agbanwe nke na-arụ ọrụ nke ọma n'ịgwọ ọrịa kansa akpa ume na-abụghị obere mkpụrụ ndụ (NSCLC). Na Eprel 9, 2025, National Medical Products Admi...GỤKWUO»

Na Machị 13, 2025, akwụkwọ akụkọ mba ụwa kachasị elu bụ́ Nature Medicine bipụtara nnwale ọgwụ mgbochi ọrịa B7-H3 nke MediLink (ADC) nke YL201 Phase 1/1b. Nnwale ahụ gụnyere akụkụ mmụba dose (phase 1) na akụkụ mmụba dose (phase 1b). E debara aha ndị ọrịa 312 n'ofe...GỤKWUO»

Na Machị 21, 2025, Immunofoco kwupụtara na Center for Drug Evaluation (CDE) n'okpuru National Medical Products Administration (NMPA) na China enyela ikike maka ọgwụgwọ EpCAM nke na-elekwasị anya na onwe ya, IMC001, maka nyocha ọhụrụ nke abụọ ya...GỤKWUO»

Na Machị 31, 2025, Innovent Biologics kwupụtara na Center for Drug Evaluation (CDE) nke National Medical Products Administration (NMPA) enyela Breakthrough Therapy Nomination (BTD) maka IBI363, protein PD-1/IL-2α-bias nke mbụ na klas nke abụọ nke antibody fusion protein, dị ka otu ọgwụgwọ maka...GỤKWUO»